← Eichor
Study identifier: NCT07516886 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy

Condition: Prostate Cancer (Post Prostatectomy) · Prostate Cancer (Adenocarcinoma) · Prostate Cancer (Diagnosis)  ·  Sponsor: Lithuanian University of Health Sciences

PhaseN/A
Planned participants500
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This prospective observational study aims to evaluate the prognostic significance of early postoperative prostate-specific antigen (PSA) levels in patients undergoing radical prostatectomy for prostate cancer. No investigational interventions will be performed. All diagnostic procedures, follow-up assessments, and treatments will be conducted in accordance with standard clinical practice and established prostate cancer management guidelines. Participation in the study will not influence treatment decisions.

This description comes directly from the study's public registry record.

Talk to the study team

Gustas Sasnauskas, MD  ·  +37063605330  ·  gustas.sas@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Lithuanian University of Health Sciences Hospital Kaunas Clinics, Department of UrologyKaunas, Kauno, LithuaniaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07516886